Korea To Bolster Fast-Track System With Speedier Approvals In Mind
This article was originally published in PharmAsia News
Executive Summary
With a broad ambition to improve the global competitiveness of its biopharma industry, South Korea is steadily unveiling supportive regulatory measures. Among the planned steps this year are the strengthening and clarification of an existing fast-track review and approval system, although the government says a limited number of reviewers may hamper the improved handling of such evaluations.
You may also be interested in...
Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister
SEOUL - Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) could be manufactured under compulsory licensing in South Korea if the country faces an emergency swine flu threat in the coming months, Health, Welfare and Family Affairs Minister Jeon Jae-Hee said
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.